Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Natural regulatory T cells control the development of atherosclerosis in mice

Abstract

Atherosclerosis is an immunoinflammatory disease elicited by accumulation of lipids in the artery wall and leads to myocardial infarction and stroke1,2. Here, we show that naturally arising CD4+CD25+ regulatory T cells, which actively maintain immunological tolerance to self and nonself antigens3,4, are powerful inhibitors of atherosclerosis in several mouse models. These results provide new insights into the immunopathogenesis of atherosclerosis and could lead to new therapeutic approaches that involve immune modulation using regulatory T cells.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Natural regulatory T cells control the development of atherosclerosis.
Figure 2: Partial depletion in CD25+ cells increases lesion size and inflammation in Apoe−/− mice but not in Apoe−/− Cd4-dnTGF-βRII mice.

Similar content being viewed by others

References

  1. Binder, C.J. et al. Nat. Med. 8, 1218–1226 (2002).

    Article  CAS  Google Scholar 

  2. Hansson, G.K. N. Engl. J. Med. 352, 1685–1695 (2005).

    Article  CAS  Google Scholar 

  3. Sakaguchi, S. Nat. Immunol. 6, 345–352 (2005).

    Article  CAS  Google Scholar 

  4. von Boehmer, H. Nat. Immunol. 6, 338–344 (2005).

    Article  CAS  Google Scholar 

  5. Daugherty, A. & Rateri, D.L. Circ. Res. 90, 1039–1040 (2002).

    Article  CAS  Google Scholar 

  6. Mallat, Z. et al. Circ. Res. 85, e17–e24 (1999).

    Article  CAS  Google Scholar 

  7. Binder, C.J. et al. J. Clin. Invest. 114, 427–437 (2004).

    Article  CAS  Google Scholar 

  8. King, V.L., Szilvassy, S.J. & Daugherty, A. Arterioscler. Thromb. Vasc. Biol. 22, 456–461 (2002).

    Article  CAS  Google Scholar 

  9. Davenport, P. & Tipping, P.G. Am. J. Pathol. 163, 1117–1125 (2003).

    Article  CAS  Google Scholar 

  10. Mallat, Z. et al. Circulation 108, 1232–1237 (2003).

    Article  CAS  Google Scholar 

  11. Almeida, A.R., Legrand, N., Papiernik, M. & Freitas, A.A. J. Immunol. 169, 4850–4860 (2002).

    Article  Google Scholar 

  12. Salomon, B. et al. Immunity 12, 431–440 (2000).

    Article  CAS  Google Scholar 

  13. Tang, Q. et al. J. Immunol. 171, 3348–3352 (2003).

    Article  CAS  Google Scholar 

  14. Buono, C. et al. Circulation 109, 2009–2015 (2004).

    Article  CAS  Google Scholar 

  15. Robertson, A.K. et al. J. Clin. Invest. 112, 1342–1350 (2003).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Inserm and by Assistance Publique-Hôpitaux de Paris as a Contrat d'Interface (to Z.M.). Inserm U689 and the Center for Molecular Medicine at Karolinska Institute are partners of the European Vascular Genomics Network, a Network of Excellence granted by the European Commission (contract LSHM-CT-2003-503254). We are indebted to B. Levacher and J. Vilard for technical assistance in Q-PCR experiments, to F. Djelti for her technical support and to J. Nemeth for her assistance in the reading of pathological specimens. We are also indebted to L. Chatenoud for providing us with the 2G7 TGF-β–specific antibody and for discussions. H.A.-O. was supported by Fédération Française de Cardiologie.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ziad Mallat.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Fig. 1

Transferred CD4+CD25+ regulatory T cells survive in vivo, retain Foxp3 expression and inhibit proliferation of CD25 deficient cells through Tgf-β and cell-cell contact. (PDF 80 kb)

Supplementary Fig. 2

Transferred CD4+CD25+ regulatory T cells retained high levels of Tgf-β mRNA expression. (PDF 40 kb)

Supplementary Fig. 3

CD4+CD25+ regulatory T cells (Treg) induce a switch toward an anti-inflammatory cytokine profile. (PDF 38 kb)

Supplementary Methods (PDF 42 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ait-Oufella, H., Salomon, B., Potteaux, S. et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12, 178–180 (2006). https://doi.org/10.1038/nm1343

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1343

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing